Predict your next investment

Madison Vaccines company logo
HEALTHCARE | Drug Development
madisonvaccines.com

See what CB Insights has to offer

Founded Year

2012

Stage

Series A - II | Alive

Total Raised

$10M

Last Raised

$2M | 7 yrs ago

About Madison Vaccines

Madison Vaccines (MVI) is focused on the development of therapeutic plasmid DNA vaccine products for patients with prostate cancer. MVI is also developing a sensitivity test to identify those patients who will derive clinical benefit from these vaccines.

Madison Vaccines Headquarter Location

505 South Rosa Road Suite 201

Madison, Wisconsin, 53719,

United States

608-467-5269

Latest Madison Vaccines News

Madison Vaccines Incorporated Appoints Jeff Bailey to Its Board of Directors

Oct 26, 2017

Madison Vaccines Incorporated Appoints Jeff Bailey to Its Board of Directors Mr. Bailey Brings 30 Years of Expertise to MVI, a Company DevelopingActive Immunotherapies for All Stages of Prostate Cancer October 26, 2017 09:13 AM Eastern Daylight Time MADISON, Wis.--( BUSINESS WIRE )--Madison Vaccines Incorporated (MVI) today announced the appointment of Jeff Bailey to the Company’s Board of Directors. Mr. Bailey brings nearly 30 years of experience based on a diverse set of leadership positions to aid MVI’s mission to bring immunotherapies to their full potential for treating prostate cancer. Mr. Bailey has a track record of delivering compelling business performance based on building and leading teams in both mature and early stage organizations. Most recently, he was the Chairman and CEO of Neurovance, leading its acquisition by Otsuka earlier this year. Previously, he served as President and CEO of Lantheus Medical Imaging Inc., leading the company to a successful IPO. He also served as COO of Fougera Pharmaceuticals (acquired by Novartis), Chief Commercial Officer for King Pharmaceuticals (acquired by Pfizer), and held earlier executive positions at Novartis Pharmaceuticals as well as at Johnson and Johnson (including Janssen Pharmaceuticals). Mr. Bailey recently served on the board of Landauer, Inc. (NYSE – LDR) up through their acquisition by Fortive in September of this year. Mr. Bailey earned a business degree from Rutgers University. “Jeff’s strong pharma background and diverse corporate governance experience will be invaluable as we advance our pipeline of immune-activating therapies for men with all stages of prostate cancer,”said Richard R. Lesniewski, PhD, President and CEO of MVI. “Jeff has had direct accountability for operational and commercial execution within major organizations, and has led multiple successful business transitions, spanning partnerships, IPO’s, and company acquisitions. We are eager to leverage his deep leadership experience across this entire business spectrum to help ensure MVI’s future success.” Although commonly referred to as “vaccines,” MVI-816 and MVI-118 are actually forms of gene-based immunotherapy. They are taken up by cells to stimulate specific immune responses using the body’s natural mechanisms to fight the cancer. MVI-118, targeting the androgen receptor, is being explored in metastatic prostate cancer to prolong disease control in men beginning Androgen Deprivation Therapy (ADT). MVI-816 is in a Phase 2 trial in non-metastatic disease to determine its effectiveness in delaying or preventing metastases, and possibly delaying the initiation of hormone deprivation therapy. MVI-816 is also being tested in combination with a checkpoint inhibitor, Keytruda® (pembrolizumab). The goal is to bring the full potential of immunotherapy to men with metastatic, castrate-resistant prostate cancer. Based on early signals in this clinical trial, including PSA declines, tumor regressions, and detection of vaccine-induced T-cells observed by 12 weeks, an expanded trial was announced in August, and has already enrolled multiple patients who will be offered the combination regimen for a year. MVI’s new board member Jeff Bailey commented, “Nearly three million men are living with prostate cancer in the United States today. MVI’s innovative trials are among the first to combine DNA vaccines with checkpoint inhibitors and to observe early positive clinical signals in metastatic prostate cancer. As the field endeavors to identify meaningful combinations that will ensure the efficacy of immunotherapies such as checkpoint inhibitors reach greater numbers of patients, including men with prostate cancer, MVI is well-positioned to be a compelling partner in this effort.” Both MVI-816 and MVI-118 were developed in the laboratories of Douglas McNeel, MD, PhD, at the University of Wisconsin-Madison, and exclusively licensed to MVI by the Wisconsin Alumni Research Foundation (WARF). Dr. McNeel is Professor of Medicine at the University of Wisconsin, Madison and Chief Scientific Founder and Chief Medical Officer of MVI. Dr. McNeel recently received a new award from the Prostate Cancer Foundation to help enable a second, MVI-816-plus-checkpoint inhibitor combination trial. Read more about Dr. McNeel's award at http://madisonvaccines.com/news.html#a-8-24-17 . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Madison Vaccines

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Madison Vaccines is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Madison Vaccines Patents

Madison Vaccines has filed 2 patents.

The 3 most popular patent topics include:

  • Alternative cancer treatments
  • Autoimmune diseases
  • Cancer treatments
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/10/2017

5/11/2021

Transcription factors, Experimental cancer drugs, Clusters of differentiation, Monoclonal antibodies, Immunology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/10/2017

00/00/0000

Grant Date

5/11/2021

00/00/0000

Title

Subscribe to see more

Related Topics

Transcription factors, Experimental cancer drugs, Clusters of differentiation, Monoclonal antibodies, Immunology

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.